PT - JOURNAL ARTICLE AU - Felton, Jamie L. AU - Redondo, Maria J. AU - Oram, Richard A. AU - Speake, Cate AU - Long, S. Alice AU - Onengut-Gumuscu, Suna AU - Rich, Stephen S. AU - Monaco, Gabriela SF AU - Harris-Kawano, Arianna AU - Perez, Dianna AU - Saeed, Zeb AU - Hoag, Benjamin AU - Jain, Rashmi AU - Evans-Molina, Carmella AU - DiMeglio, Linda A. AU - Ismail, Heba AU - Dabelea, Dana AU - Johnson, Randi K. AU - Urazbayeva, Marzhan AU - Wentworth, John M. AU - Griffin, Kurt J. AU - Sims, Emily K. AU - , TI - Precision Diagnostics: Using Islet Autoantibodies to Characterize Heterogeneity in Type 1 Diabetes AID - 10.1101/2023.04.18.23288756 DP - 2023 Jan 01 TA - medRxiv PG - 2023.04.18.23288756 4099 - http://medrxiv.org/content/early/2023/04/19/2023.04.18.23288756.short 4100 - http://medrxiv.org/content/early/2023/04/19/2023.04.18.23288756.full AB - Background Heterogeneity exists in type 1 diabetes (T1D) development and presentation. Islet autoantibodies form the foundation for T1D diagnostic and staging efforts. We hypothesized that autoantibodies can be used to identify heterogeneity in T1D before, at, and after diagnosis, and in response to disease modifying therapies. at clinically relevant timepoints throughout T1D progression.Methods We performed a systematic review assessing 10 years of original research studies examining relationships between autoantibodies and heterogeneity during disease progression, at the time of diagnosis, after diagnosis, and in response to disease modifying therapies in individuals at risk for T1D or within 1 year of T1D diagnosis.Results 10,067 papers were screened. Out of 151 that met data extraction criteria, 90 studies characterized heterogeneity before clinical diagnosis. Autoantibody type/target was most commonly examined, followed by autoantibody number, titer, order of seroconversion, affinity, and novel islet autoantibodies/epitopes. Recurring themes included positive relationships of autoantibody number and specific types and titers with disease progression, differing clinical phenotypes based on the order of autoantibody seroconversion, and interactions with age and genetics. Overall, reporting of autoantibody assay performance was commonly included; however, only 43% (65/151) included information about autoantibody assay standardization efforts. Populations studied were almost exclusively of European ancestry.Conclusions Current evidence most strongly supports the application of autoantibody features to more precisely define T1D before clinical diagnosis. Our findings support continued use of pre-clinical staging paradigms based on autoantibody number and suggest that additional autoantibody features, particularly when considered in relation to age and genetic risk, could offer more precise stratification. Increased participation in autoantibody standardization efforts is a critical step to improving future applicability of autoantibody-based precision medicine in T1D.Plain Language Summary We performed a systematic review to ascertain whether islet autoantibodies, biomarkers of autoimmunity against insulin-producing cells, could aid in stratifying individuals with different clinical presentations of type 1 diabetes. We found existing evidence most strongly supporting the application of these biomarkers to the period before clinical diagnosis, when certain autoantibody features (number, type) and the age when they develop, can provide important information for patients and care providers on what to expect for future type 1 diabetes progression.Competing Interest StatementEKS has received compensation for educational lectures from Medscape, ADA, and MJH Life Sciences and as a consultant for DRI Healthcare. CEM reported serving on advisory boards for Provention Bio, Isla Technologies, MaiCell Technologies, Avotres, DiogenyX, and Neurodon; receiving in-kind research support from Bristol Myers Squibb and Nimbus Pharmaceuticals; and receiving investigator- initiated grants from Lilly Pharmaceuticals and Astellas Pharmaceuticals. LAD reports research support to institution from Dompe, Lilly, Mannkind, Provention, Zealand and consulting relationships with Abata and Vertex. RAO had a UK MRC Confidence in concept grant to develop a T1D GRS biochip with Randox Ltd, and has ongoing research funding from Randox R & D. No other authors report any relevant conflicts of interest.Funding StatementFunding sources for authors include the following: JLF: DiabDocs K12 program 1K12DK13399501 (DiMeglio, Maahs PIs), The Leona M. & Harry B. Helmsley CharitableTrust Grant #230706126 (Felton PI). KG: The Leona M. and Harry B. Helmsley Charitable Trust and Sanford Health. RAO: RAO had a UK MRC confidence in concept award to develop a type 1 diabetes GRS biochip with Randox R&D and has ongoing research funding from Randox; and has research funding from a Diabetes UK Harry Keen Fellowship (16/0005529), National Institute of Diabetes and Digestive and Kidney Diseases grants (NIH R01 DK12184301 and U01DK12738201), JDRF (3SRA2019827SB, 2SRA20221261SB, 2SRA20021259SB, 3SRA20221241SB, and 2SRA20221258MB), and The Larry M and Leona B Helmsley Charitable Trust; and is supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the National Institutes for Health Research or the Department of Health and Social Care. LAD: NIH for TrialNet U01DK106993/616310820-BO, DiabDocs K12 program 1K12DK13399501, CTSI UL1TR00110801, CEM: R01DK093954, R01DK127236, U01DK127786, R01DK127308, and UC4DK104166, U54DK118638, P30 P30 DK097512), a US Department of Veterans Affairs Merit Award (I01BX001733), grants from the JDRF (3IND20221235IX) and Helmsley Charitable Trust (220705392), and gifts from the Sigma Beta Sorority, the Ball Brothers Foundation, and the George and Frances Ball Foundation. HI: K23DK129799; RJ: NIH R03DK127472 and The Leona M. and Harry B. Helmsley Charitable Trust (210305094); SAL: NIH NIAID R01 AI141952 (PI), NIH NCI R01 CA231226 (Other support), NIH NIAID 1 R01HL149676 (Other support), NIH NIDDK 1UC4DK117483 (subaward), JDRF 3SRA201985MB; SOG: NIH R01 DK12184301; SR: R01 DK122586, THE LEONA M AND HARRY B HELMSLEY CHARITABLE TRUST 220405134; JW: JDRF -SRA20221282MX, 3SRA2022109MB, 4SRA20221246MN, 3SRA-20231374MN.; MR: NIH NIDDK R01DK124395 and R01DK121843; R01DK121929A1, R01DK133881, U01DK127786, U01 DK127382 (EKS). Effort from this grant (to EKS, HI, JF) is also supported by Grant 2021258 from the Doris Duke Charitable Foundation through the COVID-19 Fund to Retain Clinical Scientists collaborative grant program and was made possible through the support of Grant 62288 from the John Templeton Foundation. Funding for the writing group meetings was provided by the Novo Nordisk Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.